Phase II study of lapatinib in combination with trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Clinical outcomes and predictive value of early [¹⁸F]fluorodeoxyglucose positron emission tomography imaging (TBCRC 003)

Nancy U. Lin, Hao Guo, Jeffrey T. Yap, Ingrid A. Mayer, Carla I. Falkson, Timothy J. Hobday, E. Claire Dees, Andrea L. Richardson, Rita Nanda, Mothaffar F. Rimawi, Nicole Ryabin, Julie S. Najita, William T. Barry, Carlos L. Arteaga, Antonio C. Wolff, Ian E. Krop, Eric P. Winer, Annick D. Van Den Abbeele

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of lapatinib in combination with trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Clinical outcomes and predictive value of early [¹⁸F]fluorodeoxyglucose positron emission tomography imaging (TBCRC 003)'. Together they form a unique fingerprint.

Phase II study of lapatinib in combination with trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Clinical outcomes and predictive value of early [18F]fluorodeoxyglucose positron emission tomography imaging (TBCRC 003)

Fingerprint

Medicine & Life Sciences

Phase II study of lapatinib in combination with trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Clinical outcomes and predictive value of early [¹⁸F]fluorodeoxyglucose positron emission tomography imaging (TBCRC 003)